Drug intelligence / Profile preview

CP-741,952

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules

Overview

CP-741,952 is a small molecule developed by Pfizer as an obesity therapy. It functions as a cannabinoid receptor CB1 antagonist. The drug reached Phase II clinical trials for obesity in the USA before its development was discontinued in July 2007.

Targets

MTTP (Microsomal triglyceride transfer protein large subunit)

Beyond the preview

Go deeper on CP-741,952.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-741,952.

Explore the full profile